Reference : Traitement des carcinomes hépatocellulaires à un stade avancé
Scientific journals : Article
Human health sciences : Gastroenterology & hepatology
Human health sciences : Oncology
Human health sciences : Surgery
http://hdl.handle.net/2268/11510
Traitement des carcinomes hépatocellulaires à un stade avancé
English
[en] Treatment of unresectable hepatocellular carcinoma at an intermediate or advanced stage
Van Daele, Daniel mailto [Centre Hospitalier Universitaire de Liège - CHU > > Gastro-Entérologie-Hépatologie >]
Belaiche, Jacques mailto [Centre Hospitalier Universitaire de Liège - CHU > > Gastro-Entérologie-Hépatologie >]
Delwaide, Jean mailto [Centre Hospitalier Universitaire de Liège - CHU > > Gastro-Entérologie-Hépatologie >]
Piront, Patricia mailto [Centre Hospitalier Universitaire de Liège - CHU > > Gastro-Entérologie-Hépatologie >]
De Roover, Arnaud mailto [Centre Hospitalier Universitaire de Liège - CHU > > Chirurgie abdominale- endocrinienne et de transplantation >]
Detry, Olivier mailto [Centre Hospitalier Universitaire de Liège - CHU > > Chirurgie abdominale- endocrinienne et de transplantation >]
Honore, Pierre mailto [Centre Hospitalier Universitaire de Liège - CHU > > Chirurgie abdominale- endocrinienne et de transplantation >]
Polus, Marc mailto [Centre Hospitalier Universitaire de Liège - CHU > > Gastro-Entérologie-Hépatologie >]
Mar-2009
Revue Médicale de Liège
Hopital de Baviere
64
3
140-147
Yes (verified by ORBi)
National
0370-629X
Liège
Belgique
[en] hepatocarcinoma ; cancer ; sorafenib
[en] Hepatocellular carcinoma is the main primitive tumor of the liver. It occurs in the setting of liver cirrhosis in more than 90% of the cases in developping countries. The prognosis depends on the size, number and extension of the tumor as well as on the severity of the underlying liver disease. The Barcelona Clinic Classification takes into account these different parameters and helps the clinician in the therapeutic decision. Some patients (around 25%) are amenable to therapy with a curative intent (liver transplantation, resection, destruction by radiofrequency). In patients with hepatocellular carcinoma at an intermediate stage, lipiodolized chemoembolization gives a survival advantage in comparison with placebo. No conventional regimen of chemotherapy has a proven survival benefit. In patients with a hepatocellular carcinoma at an advanced stage, sorafenib, an oral multi-targeted kinase inhibitor, is the first coumpound to demonstrate a significant effect on survival free of disease progression in a selected group of patients. Its toxicity profile is particularly favourable. Combination of surgical and medical therapies should be properly evaluated in clinical trials in the near future.
Professionals ; Students ; General public
http://hdl.handle.net/2268/11510

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Vandaele.RMDLg.2009.HCC.pdfPublisher postprint417.92 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.